Adamis Pharmaceuticals (ADMP) Trading Down 0%
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) dropped 0% on Monday . The stock traded as low as $3.65 and last traded at $4.00. Approximately 1,242,915 shares were traded during mid-day trading, an increase of 47% from the average daily volume of 847,815 shares. The stock had previously closed at $4.00.
ADMP has been the topic of several recent analyst reports. Maxim Group set a $5.00 target price on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, February 14th. Zacks Investment Research downgraded shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, November 20th. B. Riley set a $10.00 target price on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, November 15th. ValuEngine downgraded shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, November 30th. Finally, Raymond James Financial set a $7.00 target price on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, February 23rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $7.33.
The company has a debt-to-equity ratio of 0.06, a current ratio of 3.93 and a quick ratio of 3.79.
ILLEGAL ACTIVITY WARNING: “Adamis Pharmaceuticals (ADMP) Trading Down 0%” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.thecerbatgem.com/2018/03/14/adamis-pharmaceuticals-admp-trading-down-0.html.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.